Literature DB >> 11913948

CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction.

J C Poe1, M Hasegawa, T F Tedder.   

Abstract

B lymphocyte development and function depend upon the activity of intrinsic and B cell antigen receptor (BCR)-induced signals. These signals are interpreted, amplified, fine-tuned, or suppressed through the precise actions of specialized cell surface coreceptors, or "response regulators," that inform B cells of their extracellular environment. Important cell surface response regulators include the CD19/CD21 complex, CD22, and CD72. CD19 establishes a novel Src-family protein tyrosine kinase (PTK) amplification loop that regulates basal signaling thresholds and intensifies Src-family PTK activation following BCR ligation. In turn, CD22 limits the intensity of CD19-dependent, BCR-generated signals through the recruitment of potent phosphotyrosine and phosphoinositide phosphatases. Herein we discuss our current understanding of how CD19/CD21 and CD22 govern the emergence and intensity of BCR-mediated signals, and how alterations in these tightly controlled regulatory activities contribute to autoimmunity in mice and humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11913948     DOI: 10.3109/08830180109045588

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  19 in total

1.  CD19+IgM+ cells demonstrate enhanced therapeutic efficacy in type 1 diabetes mellitus.

Authors:  Andrew D Vonberg; Maria Acevedo-Calado; Aaron R Cox; Susan L Pietropaolo; Roberto Gianani; Steven K Lundy; Massimo Pietropaolo
Journal:  JCI Insight       Date:  2018-12-06

2.  Development of Sjogren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3.

Authors:  Cuong Q Nguyen; Hyuna Kim; Janet G Cornelius; Ammon B Peck
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

3.  Alteration of B-cell subsets enhances neuroinvasion in mouse scrapie infection.

Authors:  Christine von Poser-Klein; Eckhard Flechsig; Tanja Hoffmann; Petra Schwarz; Harry Harms; Raymond Bujdoso; Adriano Aguzzi; Michael A Klein
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

4.  Reduced CD19 expression and decreased memory B cell numbers in transient hypogammaglobulinemia of infancy.

Authors:  Hasibe Artac; Reyhan Kara; Bahar Gokturk; Ismail Reisli
Journal:  Clin Exp Med       Date:  2012-07-21       Impact factor: 3.984

5.  A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice.

Authors:  Jonathan C Poe; Veronique Minard-Colin; Evgueni I Kountikov; Karen M Haas; Thomas F Tedder
Journal:  J Immunol       Date:  2012-07-23       Impact factor: 5.422

6.  Vitamin A and immune function: retinoic acid modulates population dynamics in antigen receptor and CD38-stimulated splenic B cells.

Authors:  Qiuyan Chen; A Catharine Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-10       Impact factor: 11.205

Review 7.  CD11c+ T-bet+ memory B cells: Immune maintenance during chronic infection and inflammation?

Authors:  Gary M Winslow; Amber M Papillion; Kevin J Kenderes; Russell C Levack
Journal:  Cell Immunol       Date:  2017-07-19       Impact factor: 4.868

8.  Phenotypes and distribution of mucosal memory B-cell populations in the SIV/SHIV rhesus macaque model.

Authors:  Thorsten Demberg; Venkatramanan Mohanram; David Venzon; Marjorie Robert-Guroff
Journal:  Clin Immunol       Date:  2014-05-09       Impact factor: 3.969

9.  The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals.

Authors:  Koichi Yanaba; Jean-David Bouaziz; Takashi Matsushita; Takeshi Tsubata; Thomas F Tedder
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

Review 10.  Immune-mediated animal models of Tourette syndrome.

Authors:  Mady Hornig; W Ian Lipkin
Journal:  Neurosci Biobehav Rev       Date:  2013-01-10       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.